美国从2025年10月1日起对进口的有品牌的药品征收100%的关税,除非在美国生产,否则将冒澳大利亚负担得起的医药计划的风险。 U.S. to impose 100% tariffs on imported branded drugs starting Oct. 1, 2025, unless made in America, risking Australia’s affordable medicine program.

美国提议从2025年10月1日起对进口品牌药品征收100%的关税,除非制造商建立美国生产设施,威胁澳大利亚负担得起的医药计划。 The U.S. has proposed a 100% tariff on imported branded pharmaceuticals, effective October 1, 2025, unless manufacturers build U.S. production facilities, threatening Australia’s affordable medicine program. 这项政策可能破坏澳大利亚依赖低成本进口药物的保健系统的稳定,并扰乱全球供应链。 The policy could destabilize Australia’s healthcare system, which relies on low-cost imported drugs, and disrupt global supply chains. 虽然一些澳大利亚公司说它们没有受到影响,但股票价格最初大幅下跌。 While some Australian firms say they’re unaffected, stock prices initially dropped sharply. 后来市场在获得保证后反弹,但这一举动预示着美国更广泛的贸易转移,可能影响到全世界的公共卫生系统。 Markets later rebounded amid reassurances, but the move signals broader U.S. trade shifts that could impact public health systems worldwide.